JR14a

JR14a is a peptide-based antagonist of the complement C3a receptor (C3aR). It is a synthetic analog designed to competitively inhibit the binding of the anaphylatoxin C3a to its receptor, thereby blocking downstream pro-inflammatory and pro-fibrotic signaling pathways. In preclinical models of chronic lung allograft dysfunction (CLAD), JR14a has demonstrated the ability to attenuate fibrogenic transformation of mesenchymal cells by inhibiting oxidative stress-driven JNK phosphorylation and subsequent translational activation of collagen and other fibrotic markers. The compound is primarily used in academic research to investigate the therapeutic potential of C3aR blockade in transplant rejection, abdominal aortic aneurysms, and other fibro-inflammatory conditions.